| INTRODUCTION
Constipation is a common burdensome functional bowel disorder in which symptoms of difficult, infrequent, or incomplete defaecation predominate. 1 Management remains challenging, with constipation representing a significant healthcare burden costing up to $7522 per year per patient. 2 Despite the range of treatments available including laxatives and fibre supplements, approximately half of patients are dissatisfied with current management strategies, with the main complaint relating to limited efficacy. 3 Hence, there is an unmet need for alternative treatments for the management of constipation-related symptoms.
Probiotics are "live microorganisms that, when administered in adequate amounts, confer a health benefit to the host". 4 In the past decade, research has focused on their effectiveness in chronic constipation, possibly mediated through an effect on regulating gut dysmotility by impacting the gut microbiota, with the subsequent release of metabolites, including short-chain fatty acids (SCFA) during fermentation, [5] [6] [7] that are known to interact with the enteric nervous system and the immune system. 5 A systematic review and meta-analysis revealed 14 RCTs investigated the effect of probiotics in adults with chronic constipation 8 ; this suggested that probiotics may improve whole gut transit time (WGTT), stool frequency, and stool consistency, with subgroup analysis based upon species indicating significant effects in favour of Bifidobacterium lactis . 8 However, despite favourable results reported, the clinical importance of probiotics in constipation remains uncertain, due to small study sample sizes, high heterogeneity in the study design of the individual studies, and limitations in study methodologies, including the use of nonvalidated assessment tools. Nevertheless, the promising findings of the meta-analysis, justify further research to identify B. lactis strains that may be effective in the management of chronic constipation.
Therefore, the aim of this study was to investigate changes in gut transit time and gastrointestinal symptoms following 4 weeks consumption of a probiotic strain in a randomised, double-blind, placebo-controlled manner, in adults with constipation.
| MATERIAL AND METHODS

| Protocol
The study was a randomised, parallel-group, double-blind, placebocontrolled, adaptive randomised controlled trial (RCT). The intervention period was four weeks, while the primary outcome (change in WGTT) was assessed at week 2 (i.e., mid-intervention). Participants were recruited from the community and were required to attend five study visits: the screening visit, where informed consent was taken, inclusion/exclusion criteria assessed, and eligible participants enrolled to the study; the baseline visit, where final eligibility tests and randomisation were undertaken, and assessment of clinical, physiological, and stool microbiological outcomes was performed; the mid- 
| Participants
Adults from the general population with mild constipation were enrolled to this study. Inclusion criteria were: 18-65 years old; selfreported stool frequency of 3 or less bowel movements per week;
self-reported stool consistency of type 1-4 on the Bristol Stool Form Scale; fulfilment of modified Rome III diagnostic criteria for functional constipation 9 ; mild constipation determined using a score of ; high anxiety and depression score defined as a score >11
on the Hospital Anxiety and Depression Score (HADS) questionnaire, and ongoing alcohol, drug, or medication abuse. At the baseline visit and prior to randomisation, participants with short whole gut transit time (WGTT), defined as <24 hours measured using radio-opaque markers were also excluded, as were participants reporting being 'markedly better' between screening and baseline (score +3 on the Global Constipation Symptom Score at baseline visit).
| Randomisation, blinding, and study products
After fulfilling eligibility criteria at the baseline visit, participants were randomly allocated to either the probiotic or placebo. Dynamic allocation (minimisation) was chosen, and randomisation was performed through Medidata Balance (www.imedidata.com) by the study team at baseline visit. The latter was set up independently and was not accessible by the study site staff except when receiving an allocation assignment for a specific patient at the baseline visit, ensuring allocation concealment. Randomisation was stratified by gender and, for females, by menstrual cycle phase at baseline (midfollicular/mid-luteal/post-menopausal), as both have been shown to influence WGTT. 12, 13 Once randomisation was performed online, Medidata Balance would display the product code (PrXXX) the participant had been allocated to. Patients and investigators were blinded to the treatment allocation and blinding was maintained until the end of the data analysis.
The probiotic group received spray-dried B. lactis NCC2818 at a dose of 1.5 × 10 10 CFU/d, with a minimum end of shelf-life count of 8 × 10 9 CFU/d, while the placebo received maltodextrin powder.
The study products were supplied by Nestlé (Switzerland) in a milk powder-based format and packaged in aluminium sachet sticks, with each stick containing 24 g of powder. The base composition of the study products was matched and final B. lactis and placebo products were indistinguishable in terms of appearance, colour, texture, and flavour. Participants were instructed to consume the contents of one stick mixed with 200 mL of water each day for 4 weeks. All study products were refrigerated (4-8°C) both at the study site and by the participants throughout the intervention period. Viability of the probiotic in sachets was assessed and confirmed during and at the end of the study by Nestlé.
| Clinical outcomes
The primary outcome was change in WGTT after 2 weeks (i.e., baseline vs mid-intervention) between probiotic and placebo. The secondary clinical outcomes included stool output, constipation symptoms and severity, and constipation-related quality of life.
Palatability and compliance with the study product, as well as dietary intake, physical activity, and anxiety and depression, were also assessed.
| Whole gut transit time
Whole and regional gut transit times were assessed using a standard radio-opaque markers (ROM) technique. 14 Participants were provided with a box containing 12 capsules, each containing six ring markers (PRODIMED®; Plastimed, Le Plessis-Bouchard, France). Participants ingested two capsules per day (total of 12 ROM per day)
for six consecutive days prior to the baseline, mid-intervention and end of intervention visit. On the seventh day (study visit day), an abdominal x-ray was performed to determine location of any retained markers from which both regional and WGTT could be calculated.
| Stool output, constipation outcomes, and gut symptoms
Stool frequency and stool consistency were assessed using a daily stool diary and the Bristol Stool Form Scale, 15 respectively, throughout the study. The total number of bowel movements (TBM), the number of spontaneous bowel movements (SBM), and the number of complete spontaneous bowel movements were calculated based on the averages over the seven days prior to the baseline, mid-intervention and end-of-intervention visits.
Participants were also required to complete the validated CCCS, 10 Patient Assessment of Constipation Symptoms (PAC-SYM), 16 and Patient Assessment of Constipation Quality of Life (PAC-QoL) 17 at each study visit. In addition, the Global Constipation Symptom Score (GCSS) was completed at all visits except for the screening visit, to assess current symptom severity compared to those experienced at baseline on a scale from −3 (markedly worse) to +3 (markedly better). 16 Both PAC-SYM and PAC-QoL were used to define responders from nonresponders. A reduction of ≥1 point in PAC-SYM or PAC-QoL score was considered a minimal clinically important difference. 17, 18 Bloating was assessed at all visits other than the screening visit using a 100-mm visual analogue scale (VAS) anchored by the word descriptions "not at all" and "all the time" at each end. A number of GI symptoms were also measured in order to assess tolerance of the study product (abdominal discomfort, abdominal bloating/distention, flatulence, nausea) by means of a composite GI tolerance score, 6 days after the start of product consumption, and at the end of the intervention period. Participants were asked to rate the frequency and severity of these symptoms on a 5-point Likert scale ranging from 0 (absent) to 4 (very severe) over the past 24 hours, as well as over the past 6 days. 19, 20 Responses to the questions were used to calculate a mean GI tolerance score for each visit using the following formula:
Mean GI tolerance score ¼ Sum of (response to individual question Â corresponding frequencyÞ Sum of frequency for all answered questions
| Palatability and compliance
Palatability of the study product was assessed 6 days after baseline and at the end of intervention visit using a VAS anchored by the word descriptors "worst" and "best" at each end. Diaries were completed every day during the 4-week intervention period to report intake, and hence compliance, of the probiotic/placebo.
Non-compliance was defined a priori in the following three ways:
(a) participants with >2 consecutive days without any probiotic/ placebo intake during the first two weeks of the intervention period (i.e., between baseline and mid-intervention visits); or (b) >3
consecutive days without probiotic/placebo intake during the last two weeks of the consumption period (i.e., between mid and end of intervention visits); or (c) no probiotic/placebo consumption on all 3 days prior to mid-intervention visit or end of intervention visit.
| Confounding factors
A 3-day unweighed food and drink diary was completed prior to each study visit to assess dietary intake. Food diaries were analysed for nutritional composition using the Nutritics Professional Nutrition
Analysis software (Nutritics v3.74, Dublin, Ireland). Physical activity was also measured at each study visit using the validated International Physical Activity Questionnaire (IPAQ). 21 Anxiety and depression were assessed at each visit via the HADS questionnaire which contains two subscales, with seven items for anxiety (HADS-A) and seven for depression (HADS-D). 22 DIMIDI ET AL.
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| Microbiological outcomes
One fresh stool sample was collected at baseline, mid-intervention (week 2) and end of the intervention (week 4) from each participant and used for microbiological analysis. Participants were provided with a stool collection kit and were instructed to provide a fresh stool sample at the next scheduled visit or at a convenient time within 5 days from the scheduled study visit. The stool sample had to be returned to the study site no more than 3 hours following defaecation. Participants were instructed to store the fresh stool sample in a Styrofoam box with frozen gel packs (provided by the researchers) to preserve the sample in a cold temperature and minimise loss of cell viability. 23 Stool sample collection was an optional task for participants in order to reduce the burden of study participation; hence microbiology data were not available for all participants.
Quantitative polymerase chain reaction (qPCR) was used to quantify the gut microbiota in this study from phylum to species 
| Safety outcomes
Adverse events were recorded at each study visit and throughout the study using a pre-specified study document. All adverse events were summarised according to the System Organ Class (SOC) and Preferred Term (PT).
| Sample size calculation and interim analysis
The study started with two groups (high dose probiotic group vs placebo group), with the plan to perform an interim analysis that would indicate whether a third, low dose probiotic group was to be included. Hence, the sample size calculation was performed for three groups and was based on the primary outcome of change in WGTT at mid-intervention (week 2) in the high dose probiotic group compared to placebo group, using data from a previously published RCT, in which a mean change in WGTT of −28 hours (95% CI −38.9 to −17.3 hours) was observed following probiotic supplementation compared to 1 hour (95% CI −5.7 to 8.3) following placebo. 24 Assuming a power of 80% and a two-sided significance level of 5%, the sample size was estimated to be 36 participants per group with a total of 108 for all three groups. The attrition was estimated at 10% leading to an overall sample size of 120 patients across all three
groups.
An interim analysis was performed as planned by an independent panel after 39 subjects had completed the study. Based on the observed effect size and the conditional power, the panel decided that the study should continue as a two-arm RCT (high dose probiotic vs placebo) with 36 participants per group and a final sample size of 72.
| Statistical analysis
Baseline characteristics of study participants were analysed using mean and SD for continuous variables and counts and percentages for categorical variables. Continuous variables were assessed for normality using histograms and Q-Q plots. For normally distributed variables, analysis of covariance (ANCOVA) was used whereas for nonnormally distributed variables Mann-Whitney tests were used.
Changes in outcomes from baseline were compared between groups using an ANCOVA model, with the baseline measurement as a covariate, and stratification factor (menstrual cycle phase) and study group as fixed effects. Categorical outcomes were analysed using Chi-squared test.
The primary outcome was also analysed using ANCOVA, which had baseline WGTT as a covariate, and menstrual cycle phase and study group as fixed effects. The alpha (α) spent at interim analysis was 0.0032. Therefore, to control for multiple comparisons, the α was adjusted for the primary outcome analysis at α = 0.0468. Hence, a P value of <0.0468 was considered statistically significant for the primary outcome.
The majority of the statistical analysis was performed using SAS® software (version 9.4; Cary, NC, USA) except for the statistical analysis on the absolute values which was performed using IBM SPSS statistics for Windows (version 22, Armonk, New York, USA).
All analyses were performed in the intention-to-treat (ITT) population. For the microbiological outcomes, the ITT population included all the participants who provided a stool sample for each analysis and for each study time point. A per-protocol (PP) analysis was performed for the primary outcome analysis only, and consisted of all participants included in the ITT population who adhered to all protocol requirements without any major protocol deviations. Missing data were assumed to be missing at random and no imputation was performed. P values of <0.05 were considered statistically significant.
| Ethical issues
Ethical approval for the study was granted by the Camberwell St Giles NHS Research Ethics Committee (13/LO/0891). The study was registered at ClinicalTrials.gov (registration number NCT01874301).
| RESULTS
One hundred and seven participants were eligible following screening and enrolled to the study, of whom 75 were randomised and received the study product (probiotic or placebo) (Figure 1 ).
Demographic and baseline characteristics of study participants included in the ITT population are summarised in Table 1 . Excluded from analysis (n = 6)
Product compliance (n = 3)
Unauthorised medication (n = 3)
Included in safety analysis (n = 38) Included in safety analysis (n = 37)
baseline to mid-intervention between the probiotic (−11 hours, SD 32 hours) and the placebo (−17 hours, SD 33 hours)(P = 0.433).
There was no significant difference in change in WGTT from baseline to end of intervention between the probiotic (−20 hours, SD 33 hours) and placebo (−9 hours, SD 34 hours) (P = 0.103) ( Table 2 ). There were no significant differences in WGTT at baseline, mid-intervention or end of intervention between groups, although the difference at end of intervention approached significance (P = 0.062) ( Table 2 ). Regional gut transit time (left, right, and rectosigmoid) was also not significantly different between the groups (Table 2) .
No significant difference between the probiotic and placebo groups was shown for the odds of having WGTT <72 hours (i.e., upper limit of normal 25 ) at mid-intervention (OR 1.8, 95% CI 0.53-5.0) and end of intervention (OR 0.8, 95% CI 0.2-2.7).
| Stool output, gut symptoms, and constipation outcomes (Table 3)
No significant differences were observed between the probiotic and placebo in the change in total bowel movements (TBM) from baseline to mid-intervention (P = 0.836) and from baseline to end of intervention (P = 0.831). Similarly, no differences were found for spontaneous bowel movements (SBM) and complete spontaneous bowel movements (CSBM). Furthermore, no significant differences were observed between the probiotic and placebo groups in the change in stool consistency from baseline to mid-intervention (P = 0.848) and end of intervention (P = 0.936). No significant difference was observed for the change from baseline in GI tolerance or bloating between the groups during the intervention period.
There was no significant difference between the probiotic and placebo groups in the change in PAC-SYM global score from baseline to mid-intervention (P = 0.474), end of intervention (P = 0.780), and follow-up (P = 0.907) (Table 4) . Similarly, no significant difference was observed between the probiotic and placebo groups in the change in the abdominal, rectal, and stool sub-scores, at any of the study time points (Table S1 ).
In accordance with the lack of difference found for WGTT, stool output, and symptom scores, no significant difference was found between the probiotic and placebo in the change with respect to PAC-QoL global score from baseline to mid-intervention (P = 0.836), end of intervention (P = 0.315), and follow-up (P = 0.977) (Table 4) .
Similarly, no change was observed in the PAC-QoL sub-scores between the two groups at any of the study time points (Table S2 ).
Furthermore, there was no significant difference in the change from baseline in CCCS and GCSS scores between the probiotic and placebo group at any study time points (Table 4 ).
There was no significant difference in the number of responders (defined as a reduction of ≥1 point in PAC-SYM) between the probiotic and placebo at mid-intervention (n = 0 in both groups; P = 1.000), end of intervention (n = 2, 5% vs n = 2, 5%; P = 1.000), and follow-up (n = 4, 11% vs n = 1, 3%; P = 0.356). Similarly, there was no significant difference in the number of responders (defined as a reduction of ≥1 point in PAC-QoL) between the probiotic and placebo at mid-intervention (n = 1, 3% vs n = 0, 0%; P = 1.000), end of intervention (n = 1, 3% vs n = 0, 0%; P = 1.000), and follow-up (n = 1, 3% vs n = 0, 0%; P = 1.000).
| Palatability and compliance
At mid-intervention, no significant difference was observed in palatability between the probiotic and placebo in the ITT population (6.5, SD 4.3 vs 6.3, SD 5.5; P = 0.861), nor were there differences at the end of intervention (6.3, SD 4.3 vs 4.3, SD 6.6) (P = 0.107). Thirtythree (89%) participants in the probiotic group and 35 (92%) in the placebo group complied with the study product intake.
| Confounding factors
There was no significant difference in energy, protein, carbohydrate, fibre, and non-starch polysaccharide intakes between the probiotic and placebo groups at any of the study time points (Table S3 ). There was a significantly higher fat intake at baseline and the end of the intervention (week 4) in the placebo group compared to the probiotic group (P = 0.001 and P = 0.036, respectively), although the mean difference between the two groups was lower compared to baseline and mid-intervention. However, when the percentage of energy from fat was calculated, there was no difference between the probiotic (34%, SD 6%) and placebo (36%, SD 6%) groups at the end of the intervention (P = 0.388).
There were no significant differences in physical activity METs between the probiotic and placebo groups at any of the study time points (Table S4 ). There was also no significant difference in the Numbers in each group: n = 36 probiotic; n = 38 placebo.
change from baseline for the HADS total score, as well as for the anxiety and depression subscale scores, between the study groups at any of the study time points (Table S5 ).
| Microbiological outcomes
Fifty-two participants provided stool samples at baseline, 50 at mid-intervention (week 2), and 47 at the end of intervention (week 4). Forty participants provided a stool sample at each time point, while 61 participants provided stool samples at least at one time point.
There were no significant differences in any of the microbiota measured between the probiotic and placebo group at baseline, midor end of the intervention (Table 5 ). There were also no significant differences in any of the SCFA between the probiotic and placebo groups at any of the study time points (Table 5) . Similarly, there were no significant differences in stool pH or water between the probiotic and placebo groups at any of the study time points (Table 5 ).
| Adverse events
A summary of all the AEs during the study is presented in Table S6 .
There was no AE that resulted in interruption or dose reduction of the study product. One participant in the probiotic group and one in the placebo group experienced serious adverse events that were unrelated to the study product (trauma caused by car accident and arm fracture). 
T A B L E 2 Whole gut transit time (WGTT) and regionals gut transit time (in hours) in the intention-to-treat population
| DISCUSSION
The aim of this trial was to investigate changes in gut transit time and gastrointestinal symptoms following 4 weeks consumption of a probiotic strain in a randomised, double-blind, placebo-controlled manner, in adults with constipation.
There was no significant difference between the probiotic and placebo in changes in WGTT from baseline to mid-intervention and end of intervention. These results are unexpected, as a previous study has shown a significant decrease in WGTT following the consumption of another B. lactis strain, HN019. 24 Similarly, two systematic reviews and meta-analyses-that investigated the effect of N: Number of participants in groups, n: Number of participants with available data. All P values are obtained from ANCOVA test(s) adjusted for covariates (baseline values, stage of menstrual cycle), except for the p value for baseline data, which is obtained from independent t test(s). PAC-SYM and PAC-QoL subscores can be found in Table S1and S2, respectively. However, it is well known that the effects of probiotics are strain-specific. 4 Some actions of probiotics are common to a range of strains, such as metabolite production, 4 whereas others appear to be strain-specific, such as neurological effects. 27 The conflicting results between the lack of effect of the B. lactis NCC2818 strain tested in this study and the beneficial effects shown by other B. lactis strains 28 could be explained by inter-strain genomic and functional differences, such as immunogenic properties. 29, 30 As the . In addition, the placebo used in this study also resulted in a similar effect size to the placebo effect observed in many other studies assessing the effect of probiotics in the management of lower GI symptoms. 32 Other factors that could have potentially contributed to changes seen in the placebo group were considered. Firstly, the placebo powder contained maltodextrin, which is a sugar absorbed in the small intestine and, in theory, in high doses it may be less efficiently absorbed resulting in its colonic fermentation; however, this has not been previously proven, and maltodextrin has been successfully used as a placebo in numerous trials in constipation, with a meta-analysis showing no change on WGTT. 8 Secondly, physical activity has been associated with changes in gut motility 33, 34 ; however, this study showed no differences in physical activity between groups. Thirdly, there was a significantly higher fat intake in the placebo group, compared to the probiotic group. Although an association between fat intake and constipation has been demonstrated, 35 no studies have conclusively shown a causative effect of fat in constipation.
The current study also revealed no differences in stool frequency, consistency, GI tolerance, QoL and constipation-related symptoms (eg, CCCS, PAC-SYM). These results are in line with the lack of impact on WGTT, while differing with the findings of the aforementioned meta-analysis, which showed that other B lactis strains significantly increased stool frequency by an average of 1.5 bowel movements per week, and improved stool consistency and other constipation-related symptoms. 8 However, methodological differences between the current and previous studies may account for these findings. For example, Waller et al, measured weekly stool frequency using a VAS score, instead of completing daily bowel diaries. 24 Furthermore, whereas the current study used the internationally accepted Rome III criteria to diagnose chronic constipation, others have used a variation of less stringent definitions for diagnosing constipation, for example, based on stool frequency or WGTT alone. 24, 36, 37 There are also other factors that could justify the lack of effect seen in the current study. Firstly, this study was not powered for any of the clinical endpoints and, hence, the sample size may have been too small to detect a significant difference in the symptoms and quality of life. Secondly, the mean stool frequency at baseline in both groups (assessed from daily bowel diaries) was more than three bowel movements per week, which is within the range of defaecation frequency for non-constipation people. 38 This is probably due to participants underestimating their stool frequency at screening.
Thirdly, only people with mild constipation, assessed using the CCCS questionnaire (score [8] [9] [10] [11] [12] [13] [14] [15] , were included in this study. As previous systematic-reviews and meta-analyses have shown a significantly ANCOVA P value using baseline values as covariate, except for the P value for baseline data, which is obtained from independent t test(s).
greater effect of probiotics in constipated individuals compared to healthy volunteers, the lack of effect of this probiotic could be potentially due to the presence of only mild constipation symptoms. 39 Moreover, a study in IBS has shown that patients with severe symptoms had the greatest reductions in symptom severity and the largest improvements in QoL following standard medical treatment, when compared to those with mild or moderate symptoms. 40 Therefore, it is likely that the inclusion of participants with mild constipation could have limited the potential of B. lactis NCC2818 to reduce constipation-related symptoms, and could perhaps account for the differences in efficacy observed with others using B lactis strains.
Previous studies in chronic constipation have shown that not all treatments work for all pathophysiologies of constipation, likely due to the different underlying mechanisms involved. 41 The absence of severe proctological and evacuatory disorders in the present study was determined based on the participants' reported medical history, rather than on diagnostic investigation, such as proctography. Therefore, the potential heterogeneity in the pathophysiology of the study population may have contributed to the lack of effect.
In line with the findings on the clinical outcomes, there were no significant differences or changes in the stool microbiota following the consumption of the probiotic. Of note, no differences were observed in Bifidobacterium concentrations; this is a surprising finding as the probiotic consumed belonged to the Bifidobacterium genus and, therefore, an increase in Bifidobacterium in the probiotic group was expected. The lack of an increase in bifidobacteria could be explained in several ways. Firstly, it is possible that, although there might have been an increase in the B lactis strain concentration in the gut, this could have been accompanied by a simultaneous decrease in endogenous Bifidobacterium species, possibly due to outcompetition. However, the current literature does not support this theory; previous studies that have investigated the effect of probiotics on the gut microbiota have shown increases in the species to which the probiotic belonged. 6, 7 Secondly, the fact that there was no increase in bifidobacteria in the probiotic group may suggest that this B. lactis-specific probiotic strain did not survive through the GI tract, although strain survival in the faeces was not measured per se due to lack of a validated analytical method for the specific strain.
Previous human studies that have administered other B lactis strains have successfully confirmed the strain survival by measuring its stool concentration using culture methods and qPCR. 6, 42 Survival of the strain is considered a key requirement of probiotics and can be affected by several host and product-specific factors, such as age, diet, and baseline microbiota composition. Probiotic survival can also be influenced by exposure to low pH conditions of the stomach and bile acids, which can be tested in vitro. 43 In fact, the survival of the B. lactis strain used in this study has been tested and confirmed in vitro following simulated gastric and duodenal conditions. Baseline microbiota composition is also a crucial factor for the survival of probiotics due to competition for substrates and binding sites 44 ; it is, thus, possible that the probiotic provided in this study was out-competed by the gut microbiota and, hence, was not viable in the colon.
However, the lack of effect of the probiotic on the stool microbiota is in agreement with the findings of a systematic review of seven RCTs, which investigated the effect of probiotic supplementation on the stool microbiota and revealed that probiotics had no effects on the stool microbiota composition in terms of α-diversity, richness, or evenness when compared to placebo. 45 Other limitations involve the formula of the probiotic, which has not been previously studied in chronic bowel disorders. A meta-analysis of Helicobacter pylori eradication by probiotics delivered in fermented milk products showed that efficacy was better than that of capsule/sachet-based bacteria-only preparations. 46 This is also supported by animal studies that suggest that fermented milk might augment probiotic functionality when compared to water or saline carriers. 47, 48 Therefore, the fact that the B. lactis was delivered in the form of a powder in the current study could have limited the activity or survival of the probiotic and hence its efficacy. Additionally, the results of the microbiological analysis might not be representative of all stools passed by the participants throughout the study since participants provided only one stool sample per time point.
There were no differences in SCFA concentrations between the probiotic and the placebo groups. Short-chain fatty acids are produced via fermentation by colonic bacteria. This study showed that the microbiota remained stable throughout the intervention period and, therefore, the lack of effect on end-products of bacterial fermentation, including SCFA, is unsurprising. Moreover, determination of SCFA production is challenging because the majority are produced in the proximal colon and more than 95% are rapidly absorbed in that region (ie, <5% of SCFA are present in faeces); therefore, SCFA concentrations are considerably higher in the proximal colon compared to the distal colon, and the majority are unlikely to be detected in faeces. 49 Notably, the vast majority (92%) of the study population consisted of females, highlighting the fact that the findings of this study cannot be extrapolated to male members of the public. Further, the study population was recruited from the community and, therefore, the findings cannot be generalised to patients in primary, secondary, or tertiary care. However, despite the limitations, there are considerable strengths which include the randomised, double-blind design, large sample size, and use of the established formal Rome III diagnostic criteria (modified) and validated outcome assessment tools.
Furthermore, an objective measure, WGTT, was used to investigate the primary outcome.
| CONCLUSION S
This study has demonstrated that a 4-week intervention of B. lactis NCC2818 did not result in greater reduction in WGTT, nor impact other constipation-related outcomes, such as stool frequency and stool consistency, in a strictly defined population with chronic mild constipation. This is in contrast to previous studies that have demonstrated a beneficial effect of other B lactis strains in chronic constipation. Furthermore, this strain did not result in differences or changes in stool microbiota, including Bifidobacteria concentrations, stool SCFA, stool pH and stool water content. Further studies are needed in order to establish which probiotic strains, if any, are the most efficacious for the management of chronic constipation.
